期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到2篇文章
< 1 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Research on the Clinical Value of Traditional Chinese Medicine Formulas for Promoting Blood Circulation and Resolving Stasis in Treating Blood Stasis Syndrome 认领 引用
1
作者 DONG Fan 《外文科技期刊数据库（文摘版）医药卫生》 2026年第4期073-077,共5页
Objective: To evaluate the clinical efficacy of a traditional Chinese medicine (TCM) formula for promoting blood circulation and resolving stasis in patients with blood stasis syndrome in internal medicine and to asse... Objective: To evaluate the clinical efficacy of a traditional Chinese medicine (TCM) formula for promoting blood circulation and resolving stasis in patients with blood stasis syndrome in internal medicine and to assess its safety profile. Methods: A total of 80 patients with blood stasis syndrome admitted to our hospital from January to December 2024 were randomly divided into two groups of 40 each. The control group received conventional Western medication (aspirin enteric-coated tablets combined with Compound Danshen Tablets), while the observation group was treated orally with a TCM formula containing peach kernel, safflower, and danshen. Both groups underwent an 8-week treatment course. The scores for blood stasis symptoms, overall clinical efficacy rate, and incidence of adverse reactions were compared between the two groups. Results: Prior to treatment, the total scores for blood stasis symptoms were similar between the two groups (P> 0.05). After treatment, the observation group exhibited lower scores for blood stasis symptoms and a higher overall clinical efficacy rate than the control group (P 0.05). Conclusion: The TCM formula for promoting blood circulation and resolving stasis significantly alleviates clinical manifestations of blood stasis syndrome in internal medicine patients, enhances overall therapeutic outcomes, and demonstrates low adverse reaction rates, indicating good clinical safety. 展开更多
关键词 Blood-activating and stasis-resolving method Clinical application in internal medicine of Traditional Chinese Medicine Practical experience
暂未订购 下载PDF
Treatment of Posthepatitic Cirrhosis by Fuzheng Huayu Tablet(扶正化瘀片) for Reinforcing Qi and Resolving Stasis 认领 引用 被引量：23
2
作者 邓鑫 梁健 +2 位作者 刘振威 吴发胜 李璇 《Chinese Journal of Integrative Medicine》 SCIE CAS 2013年第4期289-296,共8页
Objective： To investigate the efficacy and safety of the Fuzheng Huayu Tablet （扶正化瘀片, FZHYT）, which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis （PHC）. Methods： A mult... Objective： To investigate the efficacy and safety of the Fuzheng Huayu Tablet （扶正化瘀片, FZHYT）, which is used to reinforce qi and resolve stasis in patients with posthepatitic cirrhosis （PHC）. Methods： A multicenter, randomized, controlled clinical trial was conducted in 180 patients with PHC. The patients were randomly assigned using random numbers to a treatment group treated with FZHYT and a placebo group; the treatment course was 6 months for both groups. Overall response, adverse events （AEs）, and the 2-year survival rate were assessed after treatment. Evaluations were made on changes in liver function, liver fibrosis, coagulation, hemodynamics, degrees of esophagogastric varices, ascites, quality of life （QOL）, and scores of main symptoms. Results： The overall response was significantly higher in the treatment group than the placebo group （86.7% vs. 62.2%, P〈0.01）. Patients in both groups had significant improvements in liver function [total bilirubin （TBIL）, albumin （ALB）], liver fibrosis [hyaluronic acid （HA）, type 1V collagen （CIV）], coagulation [prothrombin time （PT）, activated partial thromboplastin time （APTT）, fibrinogen （FIB）, and thrombin time （TT）], hemodynamics portal venous flow （PVF）, and splenic vein flow （SVF） after treatment. Between-group comparisons showed that compared with the placebo group patients in the treatment group achieved significantly greater improvements in TBIL, ALB, HA, C IV, PT, AP＇I-r, PVF, SVF, time to ascites resolution, 2-year survival, QOL, and symptom scores （P〈0.05 or P〈0.01）. There were no significant AEs during the treatment. Conclusion： FZHYT is effective and safe for the treatment of hepatic cirrhosis as it is associated with improved liver function, liver fibrosis, coagulation, portal hypertension state, QOL, 2-year survival rate, and fewer AEs. 展开更多
关键词 posthepatitic cirrhosis Fuzheng Huayu Tablet blood-activating stasis-resolving clinical trial
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈